Expression and clinical significance of S100A11 in non-small cell lung cancer

doi:10.3760/cma.j.issn.1673-422X.2016.01.002

Abstract

Abstract: Objective To investigate the expression of S100A11 protein in nonsmall cell lung cancer (NSCLC) and its association with clinical and pathological characteristics. MethodsThe expressions of S100A11 protein in 112 NSCLC tumor tissues (group A), tumoradjacent tissues (group B) and 10 normal lung tissues (group C) were detected by immunohistochemical SP method. The association of S100A11 expression with clinical pathological characteristics was analyzed. ResultsThe percentage of the cases with high expression cases of S100A11 protein was 78.6% (88/112), and the low expression rate was 21.4 % (24/112) in group A. The low expression rate of S100A11 protein was 100.0% (112/112) in group B. The negative expression rate of S100A11 protein was 100.0% (10/10) in group C. The difference of S100A11 expression among the three groups was statistically significant (χ2=153.634, P<0.001). The S100A11 expression was associated with pathological type (χ2=6.807, P=0.009), differentiated degree (χ2=5.029, P=0.025), regional lymph node metastasis (χ2=11.721, P=0.001) in NSCLC, but it was not associated with gender (χ2=0.020, P=0.888), age (χ2=0.816, P=0.366) and tumor size (χ2=0.406, P=0.524). ConclusionS100A11 is highly expressed in NSCLC, which is closely related with biological behavioral characteristics. S100A11 may participate in the occurrence and development of NSCLC, and it is expected to become the potential target of diagnosis and prognosis in patients with NSCLC.

Key words: Carcinoma, non-small-cell lung, Immunohistochemistry, S100A11

Chen Xiaoping, Pu Yong, Feng Jingjie, Hua Dong. Expression and clinical significance of S100A11 in non-small cell lung cancer[J]. Journal of International Oncology, 2016, 43(1): 5-7.

References

［1］ Emberley ED, Murphy LC, Watson PH. S100 proteins and their influence on prosurvival pathways in cancer［J］. Biochem Cell Biol, 2004, 82(4): 508-515. DOI:10.1139/o04-052. ［2］Bresnick AR, Weber DJ, Zimmer DB. S100 proteins in cancer［J］. Nat Rev Cancer, 2015, 15(2): 96-109. DOI:10.1038/nrc3893. ［3］刘睿, 张贺龙. S100蛋白家族成员与肿瘤关系的研究进展［J］. 现代肿瘤医学, 2010, 18(1): 200-202. DOI:10.3969/j.issn.16724992.2010.01.077. ［4］Melle C, Ernst G, Schimmel B, et al. Colonderived liver metastasis, colorectal carcinoma, and hepatocellular carcinoma can be discriminated by the Ca(2+)binding proteins S100A6 and S100A11［J］. PLoS One, 2008, 3(12): e3767. DOI:10.1371/journal.pone.0003767. ［5］杨欣, 薛丽燕, 郭蕾, 等. 多种肿瘤标志物在肺腺癌中的表达及预后意义的研究［J］. 中国肺癌杂志, 2014, 17(3): 243-253. DOI:10.3779/j.issn.10093419.2014.03.11. ［6］Chen JH, Ni RZ, Xiao MB, et al. Comparative proteomic analysis of differentially expressed proteins in human pancreatic cancer tissue［J］. Hepatobiliary Pancreat Dis Int, 2009, 8(2): 193-200. ［7］Wang G, Wang X, Wang S, et al. Colorectal cancer progression correlates with upregulation of S100A11 expression in tumor tissues［J］. Int J Colorectal Dis, 2008, 23(7): 675-682. DOI:10.1007/s00384-008-0464-6. ［8］F Lam F, Jankova L, Dent OF, et al. Identification of distinctive protein expression patterns in colorectal adenoma［J］. Proteomics Clin Appl, 2010, 4(1): 60-70. DOI:10.1002/prca.200900084. ［9］Shiota M, Tsunoda T, Song YH, et al. Enhanced S100 calciumbinding protein P expression sensitizes human bladder cancer cells to cisplatin［J］. BJU Int, 2011, 107(7): 1148-1153. DOI:10.1111/j.1464-410X.2010.09535.x. ［10］ Rehman I, Azzouzi AR, Cross SS, et al. Dysregulated expression of S100A11 (calgizzarin) in prostate cancer and precursor lesions［J］. Hum Pathol, 2004, 35(11): 1385-1391. DOI:10.1016/j.hum-path.2004.07.015. ［11］ Hao JT, Wang K, Yue Y, et al. Selective expression of S100A11 in lung cancer and its role in regulating proliferation of adenocarcinomas cells［J］. Mol Cell Biochem, 2012, 359(1/2): 323-332. DOI:10.1007/s11010-011-1026-8.

[1]	Liao Lihua, Wang Shaohong, Chen Hongcai, Zhao Yongqiang. Value of cell paraffin block immunohistochemistry and pleural effusion CRKL and MIC-1 in the diagnosis of malignant pleural effusion [J]. Journal of International Oncology, 2023, 50(2): 71-75.
[2]	Xue Dong, Xia Xiuliang, Song Dekun, Xiang Tinghai, Wang Jianqiang, Gong Bengang. Expression and clinical significance of cullin 4A in cholangiocarcinoma [J]. Journal of International Oncology, 2019, 46(3): 153-156.
[3]	Duan Fei, Zhang Jinyu, Liu Jing, Ma Zhenfeng, Cui Naipeng, Liu Xianyi, Chen Baoping. Expression and clinical significance of OTUB1 in breast cancer [J]. Journal of International Oncology, 2017, 44(8): 565-568.
[4]	Huang Lijuan, Zhou Bingjuan, Cao Jianjiang, Zhang Nan, Chen Hong, Ma Qiushuang, Zhang Jinku. Expressions and clinical significances of ATF3 and Runx2 in breast carcinoma [J]. Journal of International Oncology, 2017, 44(6): 411-.
[5]	Teng Fei, Cui Guimin, Shi Hongyun, Liu Miaoling, Li Yanhong. Clinical observation of radiotherapy combined with temozolomide in non-small cell lung cancer patients with brain metastases [J]. Journal of International Oncology, 2017, 44(4): 271-273.
[6]	Lin Chenshi, Yang Jiyuan. Expression of RRM1 in gastric adenocarcinoma and its relationship with clinical pathological characteristics [J]. Journal of International Oncology, 2016, 43(5): 343-345.
[7]	Huang Liyong, Pan Jie, Shen Xuning, Jiang Honggang. Expression and significance of Sirtuin 1 in human colorectal cancer [J]. Journal of International Oncology, 2016, 43(3): 188-192.
[8]	ZHANG Zhi-Jin, FU Jun, ZHANG Yu-Hao, GE Cui-Cui, QIN Xian-Ju. Pre-B-cell colony enhancing factor expression and its clinical significance in colorectal cancer [J]. Journal of International Oncology, 2016, 43(12): 896-899.
[9]	Nie Jia, Wu Ning, Zhang Lixia, Huang Yifan, Liu Jun. Expressions of IMP3 in cervical squamous cell carcinoma before and after the therapy of radiation and chemotherapy [J]. Journal of International Oncology, 2016, 43(10): 744-747.
[10]	WANG Rui-Cai, ZHU Jian-You, ZHANG Hai-Peng, XU Shao-Yan, WANG Ai-Yun. Expressions and clinical signifcances of matrix metalloproteinase13 and p73 in gastric adenocarcinoma [J]. Journal of International Oncology, 2015, 42(8): 576-579.
[11]	Jiang Zhongxiu, Liu Yang, Li Ning, Qi Xiaoying, Zhang Xiaoye. Expression and clinical significance of SIRT-1 and NF-κB in non-small cell lung cancer [J]. Journal of International Oncology, 2015, 42(7): 504-507.
[12]	Hu Siqin, Zhang Minghui, Shi Qiong, Wang Yan. Expression and significance of TTF1 and CgA in small cell lung carcinoma [J]. Journal of International Oncology, 2015, 42(7): 501-503.
[13]	FAN Li-Juan, ZHANG Jian, LIN Fan-Zhong, LI Hong-Yun. Expression and clinically pathological analysis of the protein CDC6 and HOXA5 in esophageal squamous cell carcinoma [J]. Journal of International Oncology, 2015, 42(5): 327-330.
[14]	CHEN Wen-Jun, DONG Chong-Hai, TIAN Zi-Bin. Expression and significance of c-myc and CD24 in colorectal cancer [J]. Journal of International Oncology, 2015, 42(4): 255-258.
[15]	Li Tingting, Kang Junpeng, Guo Shuqin. Expressions of IGF-1R and IGFBP-3 in colon cancer metastasis and their correlations with lymphatic metastasis [J]. Journal of International Oncology, 2015, 42(2): 95-98.